G
Genapsys
A company focused on the advancement of universal access to genomic information by delivering an affordable, scalable, and accurate genomic sequencing ecosystem that empowers both academic and…
About Genapsys
GenapSys operates in the biotechnology sector, specializing in DNA sequencing technology. The company has developed a novel electrical-based platform that enables accurate, scalable, and affordable sequencing. This technology is particularly useful for applications such as targeted sequencing to identify both germline and somatic mutations, as well as sequencing small genomes. GenapSys serves a diverse range of clients, including research institutions, healthcare providers, and pharmaceutical companies. The company operates in the global market, with recent expansions into Asia. GenapSys generates revenue through the sale of its sequencing platforms and related consumables. The business model is centered around providing high-accuracy sequencing solutions that are both cost-effective and scalable, making advanced DNA sequencing accessible to a broader audience.
Source: Dealroom company dataAt a glance
- Founded
- 2010
- Headquarters
- Redwood City, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Plug and Play
Decheng Capital
IPV Capital
Series B and later5 investors entered at this stage
Foresite Capital
Oxford Finance
Farallon Capital Management- SCSoleus Capital
- PGPBM Capital Group
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Genapsys on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Genapsys on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.